Dr. Andreadis Discusses Toxicities With CAR T-Cell Therapy

Video

In Partnership With:

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses toxicities associated with CAR T-cell therapy.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses toxicities associated with chimeric antigen receptor (CAR) T-cell therapy.

The main toxicities associated with CAR T-cell therapy exist in 2 broad spheres, says Andreadis. One is cytokine release syndrome (CRS), which presents with fever, low blood pressure, low oxygen level, and organ toxicity. These toxicities usually occur within the first week after therapy. The second sphere is short-term toxicities, which can be confusion, inability to speak, disorientation, tremors, and possibly coma. These also usually occur within the first week, but often last a little longer than the toxicities associated with CRS, says Andreadis.

Physicians need to be educated and trained in order to safely administer CAR T-cell therapy and manage the toxicities, Andreadis adds. Once the acute phase is over, most patients can return to their local physicians. Andreadis explains that the long-term side effects such as low blood counts are manageable, and physicians and patients should be hypervigilant about infections.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,